Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients

BACKGROUND: Abiraterone and enzalutamide use is associated with significant cardiovascular (CV) morbidity in clinical trials, but the magnitude and clinical relevance of this association in real-world prostate cancer (PC) population remain unknown. MATERIALS AND METHODS: We retrospectively reviewed...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, A.A., Rubin, N., Tholkes, A., Shah, S., Ryan, C.J., Lutsey, P.L., Prizment, A., Rao, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437777/
https://www.ncbi.nlm.nih.gov/pubmed/34509804
http://dx.doi.org/10.1016/j.esmoop.2021.100261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437777/
https://www.ncbi.nlm.nih.gov/pubmed/34509804
http://dx.doi.org/10.1016/j.esmoop.2021.100261

Ejemplares similares